News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 06/11/2026 GMT			5-day change	1st Jan Change
547.09 ^USD	+0.85%		-2.11%	+20.67%

11-04	Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $620 From $608	MT
11-03	Vertex Stock May See Further Appreciation on Approval, Launch of Povetacicept, RBC Says	MT

All News

Mentions Relevance

11-04	Vertex to Participate in Upcoming Investor Conferences	BU
11-04	Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $620 From $608	MT
11-03	Vertex Stock May See Further Appreciation on Approval, Launch of Povetacicept, RBC Says	MT
11-03	UBS Adjusts Price Target on Vertex Pharmaceuticals to $640 From $615, Maintains Buy Rating	MT
11-03	RBC Raises Price Target on Vertex Pharmaceuticals to $600 From $576, Keeps Outperform Rating	MT
11-03	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $563 From $500	MT
11-03	Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $660 From $665	MT
11-03	Scotiabank Adjusts Price Target on Vertex Pharmaceuticals to $660 From $558	MT
11-03	Cantor Fitzgerald Adjusts Price Target on Vertex Pharmaceuticals to $619 From $595	MT
11-03	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $725 From $654	MT
11-03	Barclays Adjusts Price Target on Vertex Pharmaceuticals to $626 From $617	MT
11-03	Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $650 From $550	MT
11-03	BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $620 From $600	MT
11-03	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $575 From $550	MT
11-03	JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $570 From $560	MT
11-02	Vertex Pharmaceuticals Incorporated, Q3 2026 Earnings Call, Nov 02, 2026
11-02	Vertex Pharmaceuticals Raises Outlook Following Crinetics Acquisition	DJ
11-02	Vertex Pharmaceuticals Q3 Adjusted Earnings Fall, Revenue Rises	MT
11-02	Vertex Pharmaceuticals Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
11-02	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Reports Q3 Revenue $3.44B, vs. FactSet Est of $3.42B	MT
11-02	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q3 Adjusted EPS $4.76 per Share, vs. FactSet Est of $4.82	MT
11-02	(VRTX) Vertex Pharmaceuticals Expects 2026 Revenue Range $13.15B-$13.25B, vs. FactSet Est of $13.26B	MT
11-02	Vertex Reports Third Quarter 2026 Financial Results	BU
11-02	Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2026	CI
10-30	UK Healthcare Regulator OKs Vertex Pharmaceuticals' Casgevy Gene Therapy for Children From Age Five	MT